Sugammadex: A selective relaxant-binding agent providing rapid reversal

Current Opinion in Anaesthesiology

Volumn 23, Issue 4, 2010, Pages 461-465

  Rex, Christopher ^a   Bergner, Urs A ^a   Pühringer, Friedrich K ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

cyclodextrin; neuromuscular blockade; reversal; sugammadex

Indexed keywords

FLUCLOXACILLIN; FUSIDIC ACID; NEOSTIGMINE; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; TOREMIFENE; ANDROSTANE DERIVATIVE; CENTRAL MUSCLE RELAXANT; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; VECURONIUM;

CLINICAL PRACTICE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; ENCAPSULATION; ERYTHEMA; FLUSHING; HUMAN; KIDNEY FUNCTION; LIPOPHILICITY; LOW DRUG DOSE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; TACHYCARDIA; URINARY EXCRETION; ANESTHESIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG INTERACTION; EMERGENCY HEALTH SERVICE;

ANDROSTANOLS; ANESTHESIA; ANIMALS; DRUG INTERACTIONS; EMERGENCY MEDICAL SERVICES; GAMMA-CYCLODEXTRINS; HUMANS; MUSCLE RELAXANTS, CENTRAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS; VECURONIUM BROMIDE;

EID: 77954656690     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833a5413     Document Type: Review

References (25)

1. Loftson T, Brewster ME. Pharmaceutical applications of cyclodextrines. 1. Drug solubiliazation. J Pharm Sci 1996; 85:1017-1023.
2. Brewster ME, Loftson T. The use of chemically modified cyclodextrines in the development of formulations for chemical delivery systems. Pharmazie 2002; 57:94-101.
3. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104:575-581.
4. Gijsenbergh F, Ramael S, Houwing N, Van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103:695-703.
5. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology 2007; 106:935-943.
6. Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104:555-562.
7. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuroniuminduced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109:816-824.
8. Rex C, Wagner S, Spies C, et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anaesthesia. Anesthesiology 2009; 111:30-35.
9. Vanacker BF, Vermeyen KM, Struys MMRF, et al. Reversal of rocuroniuminduced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007; 104:563-568.
10. Blobner M, Eriksson L, Scholz J, et al. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium induced neuromuscular blockade compared with neostigmine (50mg/kg). Eur J Anaesthesiol 2007; 24 (Suppl 39): 125. (A9AP7-10).
11. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuroniuminduced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008; 100:622-630.
12. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuroniumor vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106:283-288.
13. Pühringer F, Rex C, Sielenkämper A, et al. Reversel of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. Anesthesiology 2008; 109:188-197.
14. Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110:1020-1025.
15. Staals LM, Snoeck MMJ, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the ficacy and safety of sugammadex in patients with end-stage renal failure or ormal enal function. Br J Anaesth 2008; 101:492-497.
16. Staals LM, Snoeck MMJ, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010; 104:31-39.
17. Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110:284-294.
18. Khuenl-Brady K, Wattwil M, Vanacker B, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 2010; 110:64-73.
19. Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- and vecuronium- induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010; 110:74-82.
20. Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 104:582-584.
21. Bridion. Product information; 2008.
22. Rex C, Pühringer FK. Sugammadex: a new era in the antagonism of muscle relaxants. Anasthesiol Intensivmed Notfallmed Schmerzther 2009; 44:368-374.
23. De Boer HD, Van Egmond J, Van De Pol F, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 96:473-479.
24. Kam De PJ, Kuijk Van J, Smeets J, et al. Single iv use of sugammadex up to mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007; 105:A1580
25. Vasella FC, Frascarolo O, Spahn DR, Magnusson I. Antagonism of neuromuscular blockade but not muscle relaxation effects depth of anaesthesia. Br J Anaesth 2005; 94:742-747.